Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Wells Fargo & Co — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Wells Fargo & Co trades at $81.23 (market cap $242.35B). The key difference: Wells Fargo & Co is far larger — about 49.7× Travere Therapeutics Inc. Common Stock's market cap, and Wells Fargo & Co pays a 2.48% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Wells Fargo & Co for 88 Days on average.
| TVTX | WFC | |
|---|---|---|
Market Cap | $4.88B | $242.35B |
Volume | 1,668,577 | 25,561,701 |
Sector | Health | Financials |
52-Week High | $67.52 | $96.40 |
52-Week Low | $26.79 | $73.42 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $5.01B | $424.64B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Wells Fargo (WFC) trades at $80.91, down 2.88% on the day, amid mixed technical signals with a bullish overall trend but bearish moving averages. The bank shows strong fundamentals with a P/E of 11.74, net income margin of 25.97%, and consistent earnings beats in recent quarters. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and renewed technology agreements supporting mortgage servicing.
The stock presents a value opportunity with a consensus price target of $98.75, implying 22% upside, supported by analyst bullishness (46.66% buy ratings). Key risks include volatile cash flows, with operating cash flow negative in 2025, and sensitivity to interest rate changes as highlighted by recent Fed hikes (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
